Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival-Reference-Cited by-同舟云学术

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

Published:2017-07-31 Issue:11 Volume:6 Page:e1358331
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Cheung Irene Y.¹^ORCID,Kushner Brian H.²,Modak Shakeel²,Basu Ellen M.²,Roberts Stephen S.²,Cheung Nai-Kong V.²^ORCID

Affiliation:

1. ScD, Memorial Sloan Kettering Cancer Center, Department of Pediatrics, 1275 York Avenue, New York, NY, USA

2. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1358331

Reference32 articles.

1. GD2-Targeted Immunotherapy and Radioimmunotherapy

2. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

3. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients

4. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2

5. Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges;Cancers;2024-06-12

2. Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma;2024-05-28

3. Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects;Frontiers in Oncology;2024-05-15

4. Bilateral tonic pupils secondary to anti-GD2 antibody therapy for neuroblastoma;Journal of American Association for Pediatric Ophthalmology and Strabismus;2024-04

5. GD2-targeting therapy: a comparative analysis of approaches and promising directions;Frontiers in Immunology;2024-03-15